Iovance Biotherapeutics, Inc. IOVA
8.14 USD +0.05 (+0.68%)
Nov 11, 2026, 11:20 AM EST
8.01 Day range 8.19
2.08 52-week range 15.37
- YTD
- +197.99%
- 1 year
- +206.98%
News
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA). Such investors…
seekingalpha.com Biotech Is Booming; Here Are 4 Names Outperforming Despite This Deep Correction I build my biotech investments using technical analysis, focusing on price action and volume, not traditional fundamentals. I target small-cap biotechs advancing past Phase 2, especially those…
benzinga.com Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $19 Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $18 to $19.
benzinga.com Citizens Maintains Market Outperform on Iovance Biotherapeutics, Raises Price Target to $12 Citizens analyst Reni J. Benjamin maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Market Outperform and raises the price target from $8 to $12.
zacks.com IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs Iovance beat Q3 2026 earnings and revenue estimates as Amtagvi sales top $100 million, margins improve and R&D costs decline.
seekingalpha.com Iovance Q3 Earnings: Why I'm Reiterating My Buy Call Despite Market Reaction Iovance Biotherapeutics, Inc., delivered strong Q3 results, with revenues up ~80% YoY and gross margin rising to 60%. IOVA reaffirmed 2026 guidance of $410–$420M revenue, and maintains a robust cash…
seekingalpha.com Iovance: Reset Expectations Make The Stock A Buy Again (Rating Upgrade) Iovance Biotherapeutics, Inc. fell 46% after my downgrade to Hold in September, reflecting over-optimism in valuation. AMTAGVI's (lifileucel) melanoma launch gained momentum, but the NSCLC…
zacks.com IOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline Progress Iovance reaffirms its 2026 revenue outlook as Q3 sales jump 80%, fueled by Amtagvi adoption, improving margins and progress in its cancer pipeline.
seekingalpha.com Iovance Biotherapeutics, Inc. (IOVA) Q3 2026 Earnings Call Transcript Iovance Biotherapeutics, Inc. ( IOVA ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Jen Saunders Frederick Vogt - Interim CEO, President, General Counsel, Corporate…
marketbeat.com Iovance Biotherapeutics Q3 Earnings Call Highlights Iovance Biotherapeutics NASDAQ: IOVA reported record third-quarter revenue of approximately $122 million, up 80% from a year earlier, as sales of its melanoma treatment AMTAGVI surpassed $100 million…
benzinga.com Iovance Biotherapeutics Q3 2026 Earnings Call Transcript Iovance Biotherapeutics (NASDAQ:IOVA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
zacks.com Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Beats Revenue Estimates Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.25 per share a year ago.
benzinga.com Iovance Biotherapeutics Affirms FY2026 Sales Guidance of $410.000M-$420.000M vs $416.263M Est Iovance Biotherapeutics (NASDAQ:IOVA) affirms FY2026 sales outlook from $410.000 million-$420.000 million to $410.000 million-$420.000 million vs $416.263 million estimate.
benzinga.com Iovance Biotherapeutics Q3 EPS $(0.05) Beats $(0.09) Estimate, Sales $121.469M Beat $115.982M Estimate Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.09) by 37.5 percent. This is a 80 percent increase over losses of…
globenewswire.com Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates Total Revenue Increased ~80% and U.S. Amtagvi Revenue Increased ~77% Year-over-Year, and Gross Margin Increased to ~60% 24.6% Objective Response Rate (ORR) in 69 Patients with Non-Squamous Metastatic…
benzinga.com UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $8 UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $7 to $8.
benzinga.com Crude Oil Moves Lower; Caterpillar Shares Fall Following Q3 Results U.S. stocks fell Thursday, led by a 9% Caterpillar drop; Porch, Teladoc and Crocs surged, while oil, gold and silver declined.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Glaukos (NYSE:GKOS) shares rose 30.8% to $237.26 during Thursday's regular session. The company's market cap stands at $10.7 billion. The company's, Q3 earnings came out yesterday. Teladoc…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75%…
benzinga.com Iovance Biotherapeutics Announced Updated Results From Cohorts 1 And 2 Of Its Phase 2 IOV-LUN-202 Trial; 24.6% Objective Response Rate In 69 Patients With Non-Squamous mNSCLC, Consistent With Previously Reported Results IOV-LUN-202 Cohorts 1 and 2 Are Completing Enrollment and Support a Planned Supplemental Biologics License Application (sBLA) for Lifileucel in Non-Squamous mNSCLC in 2027KRAS Wild-Type Subgroup…
benzinga.com Iovance Biotherapeutics Reports Deep, Durable Responses With Lifileucel Monotherapy In Metastatic UPS And DDLPS At ESMO 2026 50% Confirmed Objective Response Rate (ORR) with All Responses Ongoing in an Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2026Unprecedented Efficacy in Both…- benzinga.com Iovance's Phase 2 Lifileucel Plus Pembrolizumab Delivers 62.5% ORR And 29.2% Complete Response Rate In Frontline Advanced Melanoma, With Median OS Not Yet Reached At 50.9 Months 62.5% Confirmed Objective Response Rate (ORR) and 29.2% Complete Response (CR) Rate in Final Phase 2 AnalysisMedian Overall Survival (OS) Not Reached at More than 4 Years of Median Follow-upOral…
benzinga.com Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18 Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $15 to $18.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Baird Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $11 Baird analyst Colleen Kusy maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $6 to $11.
benzinga.com Transcript: Iovance Biotherapeutics Q2 2026 Earnings Conference Call Iovance Biotherapeutics (NASDAQ:IOVA) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is…
benzinga.com Top 3 Health Care Stocks That May Collapse In Q4 Three healthcare stocks—Quantum-Si, Kodiak Sciences and Iovance—show overbought RSI readings above 80, warning momentum-focused investors.- benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
- benzinga.com Wells Fargo Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18 Wells Fargo analyst Yanan Zhu maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $14 to $18.
benzinga.com Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On? Shares of Iovance Biotherapeutics are trading slightly lower Wednesday morning, taking a breather after Tuesday's surge which pushed the stock to a new 52-week high.
benzinga.com Fair Issac Corp., Iovance Biotherapeutics, Stablecoin Development Corp., Carnival Corp. and Micron: Why These 5 Stocks Are on Investors' Radars Today FICO, IOVA, SDEV, CCL, MU were among the trending stocks on Tuesday, Sept. 29, 2026.- benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Iovance Biotherapeutics’ Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars Iovance Biotherapeutics upgrades 2026 revenue guidance to $410 million-$420 million. Key technicals, analyst targets, and Amtagvi demand analyzed.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Stablecoin Development (AMEX:SDEV) stock increased by 121.6% to $3.48 during Tuesday's regular session. The market value of their outstanding shares is at $42.5 million. Iovance…
benzinga.com Crude Oil Down 1%; US Job Openings Fall In August U.S. stocks fell as job openings declined; oil slid and gold rose. BKYI doubled, SSTI surged, while NIVF plunged 77% and QURE fell 37%.- benzinga.com HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $20 HC Wainwright & Co. analyst Joseph Pantginis maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $9 to $20.
benzinga.com CarMax Posts Upbeat Q2 Earnings, Joins Iovance Biotherapeutics, Perella Weinberg Partners And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed as Dow fell 100+ points; CarMax surged 9.7% on strong results, while Iovance, Carnival and others gained.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock…
- benzinga.com Goldman Sachs Reinstates Buy on Iovance Biotherapeutics, Announces $15 Price Target Goldman Sachs analyst Andrea Newkirk reinstates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and announces $15 price target.
- benzinga.com Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $15 Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $13 to $15.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com TD Cowen Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $10 TD Cowen analyst Nicholas Lorusso maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and raises the price target from $7 to $10.
benzinga.com Iovance Biotherapeutics Stock Is Trending Friday: What's Going On? Shares of Iovance Biotherapeutics are trending Friday morning after a momentum surge pushed the biotech stock to a new 52-week high.
benzinga.com Why Iovance Biotherapeutics Stock Hit 52-Week High Iovance Biotherapeutics stock hits a 52-week high as investors weigh Moderna-Merck cancer data, Amtagvi sales and analyst price target hikes.
benzinga.com UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $7 UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $4 to $7.
benzinga.com Deere, Coinbase Global, Nordson And Other Big Stocks Moving Higher On Wednesday Dow Jones down 300 points, Deere & Co shares up 7.9% after beating earnings expectations. SCTX, SCSC, BTBT, MRVI, HIVE, AHG, TEM, MARA, LB also gain.
benzinga.com Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.- benzinga.com Mizuho Maintains Outperform on Iovance Biotherapeutics, Raises Price Target to $11 Mizuho analyst Mara Goldstein maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Outperform and raises the price target from $10 to $11.
- benzinga.com Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $13 Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $11 to $13.
- benzinga.com Citizens Maintains Market Outperform on Iovance Biotherapeutics, Raises Price Target to $8 Citizens analyst Reni J. Benjamin maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Market Outperform and raises the price target from $5 to $8.